Form 4 for EW Edwards Lifesciences
Accepted 2026-04-09 19:34:07 ET · period of report 2026-04-09 · accession 0001225208-26-004476 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-09 19:34 | 2026-04-09 | EW | Ullem Scott B. | CFO, CVP | M - OptEx | $59.26 | +13.0K | 52.7K | +33% | +$770.3K |
| DMT | 2026-04-09 19:34 | 2026-04-09 | EW | Ullem Scott B. | CFO, CVP | S - Sale+OE | $80.04 | -13.0K | 39.7K | -25% | -$1.04M |
| DT | 2026-04-09 19:34 | 2026-04-09 | EW | Ullem Scott B. | CFO, CVP | M - OptEx | $0.00 | -13.0K | 13.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-09 | M | A | 13,000 | $59.26 | 52,699 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. |
| 2 | Common | Common Stock | 2026-04-09 | S | D | 4,676 | $80.50 | 48,023 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-04-09 | S | D | 8,324 | $79.79 | 39,699 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Derivative | Employee Stock Option (Right to Acquire) | 2026-04-09 | M | D | 13,000 | $0.00 | 13,000 | D | $59.26 · 2020-05-08 to 2026-05-07 | 13,000 Common Stock |